A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial
Authors:
Open Access
- 16 April 2021
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 12 (1) , 1-15
Abstract
Background: ABO-incompatible liver transplantation (ABO-i LT) has become a rescue therapeutic option for patients with severe hepatic failure. Although the use of rituximab greatly reduces the morbidity of antibody-mediated rejection (AMR), severe adverse effects, such as infection and biliary complications, still seriously threaten the survival of transplant recipients. The aim of this study was to evaluate the safety and feasibility of using mesenchymal stem cells (MSCs) to replace rituximab in ABO-i LT. Methods: Twenty-two patients with severe hepatic failure undergoing ABO-i LT were enrolled and randomly divided into two groups: the MSC group and the rituximab group. The safety of the application of MSCs and the incidence of allograft rejection, including antibody-mediated rejection (AMR) and acute cellular rejection (ACR), were evaluated in both groups at the 2-year follow-up period as primary endpoints. Recipients and graft survival and other postoperative complications were compared as secondary endpoints. Results: No severe MSC-related adverse events were observed during the trial. MSC treatment yielded comparable, if not better, results than rituximab at decreasing the incidence of acute rejection (9.1% vs 27.3%). Inspiringly, compared to those in the rituximab group, the rates of biliary complications (0% vs 45.5%) and infection (9.1% vs 81.8%) were significantly decreased in the MSC group. In addition, there were no significant differences in 2-year graft and recipient survival between the two groups (81.8% vs 72.7%). Conclusions: Our data show that MSC transfusion is comparable to rituximab treatment for AMR prophylaxis following ABO-i LT. Additionally, the results indicate that MSCs are more beneficial to the prevention of infection and biliary complications and may be introduced as a novel immunosuppressive approach for ABO-i LT. Trial registration: Trial registration: chictr.org.cn, ChiCTR2000037732. Registered 31 August 2020- Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=57074.Keywords
All Related Versions
Funding Information
- National Key R&D Program of China (2017YFA0104304)
- National Natural Science Foundation of China (81770648, 81802402, 81900597, 81970567)
- National Natural Science Foundation of China (81870449)
- National Key R&D Program of Guangdong Province (2019B020236003)
- Natural Science Foundation of Guangdong Province (2017A030311034, 2018A03031032, 2018A030313043)
- Medical Scientific Research Foundation of Guangdong Province (A2018130)
- Sci-tech Research Development Program of Guangzhou City (158100076)
- Young Teacher Development Program of Sun Yat-sen University (17ykpy57, 19ykpy35, 20ykpy41)
- China Postdoctoral Science Foundation (2019M653199)
- Academician Shusen Lanjuan Talent foundation
This publication has 35 references indexed in Scilit:
- A comparison of desensitization methods: Rituximab with/without plasmapheresis in ABO-incompatible living donor liver transplantationHepatobiliary & Pancreatic Diseases International, 2018
- A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft RejectionStem Cells Translational Medicine, 2017
- Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysisThe Lancet Haematology, 2017
- The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced FibrosisStem Cells Translational Medicine, 2015
- Impact of Rituximab Desensitization on Blood-Type-Incompatible Adult Living Donor Liver Transplantation: A Japanese Multicenter StudyAmerican Journal of Transplantation, 2014
- Update on stem cell therapy for cerebral palsyExpert Opinion on Biological Therapy, 2011
- Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant PatientsAmerican Journal of Transplantation, 2009
- Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cellsNanotoxicology, 2009
- Mesenchymal stem cell–derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivoHepatology, 2008
- Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose TissueStem Cells, 2006